Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Short Interest Update

Share on StockTwits

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) saw a significant growth in short interest in November. As of November 29th, there was short interest totalling 4,340,000 shares, a growth of 11.6% from the November 14th total of 3,890,000 shares. Based on an average trading volume of 833,200 shares, the short-interest ratio is currently 5.2 days. Approximately 4.8% of the company’s stock are short sold.

Shares of NBIX stock traded down $0.84 during trading hours on Friday, hitting $110.59. 1,511,551 shares of the company were exchanged, compared to its average volume of 1,099,549. The company has a debt-to-equity ratio of 0.83, a quick ratio of 6.99 and a current ratio of 7.08. Neurocrine Biosciences has a one year low of $66.71 and a one year high of $119.65. The business’s 50-day simple moving average is $110.05 and its two-hundred day simple moving average is $95.60. The stock has a market capitalization of $10.43 billion, a price-to-earnings ratio of 492.39, a P/E/G ratio of 5.73 and a beta of 1.24.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.56 EPS for the quarter, missing the consensus estimate of $0.63 by ($0.07). Neurocrine Biosciences had a return on equity of 5.67% and a net margin of 3.12%. The company had revenue of $222.09 million for the quarter, compared to the consensus estimate of $211.31 million. During the same period in the previous year, the business posted $0.52 EPS. The business’s revenue for the quarter was up 46.3% on a year-over-year basis. As a group, analysts anticipate that Neurocrine Biosciences will post 0.82 EPS for the current fiscal year.

Several analysts have recently weighed in on the company. Zacks Investment Research downgraded Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. TheStreet raised shares of Neurocrine Biosciences from a “c+” rating to a “b” rating in a research report on Tuesday, November 19th. Royal Bank of Canada set a $118.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Friday, September 6th. Credit Suisse Group cut shares of Neurocrine Biosciences from an “outperform” rating to a “neutral” rating and set a $110.00 price target on the stock. in a research report on Friday. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $153.00 price target (up previously from $116.00) on shares of Neurocrine Biosciences in a research report on Thursday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the stock. Neurocrine Biosciences currently has a consensus rating of “Buy” and an average target price of $111.77.

In other news, CFO Matt Abernethy sold 1,645 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $116.33, for a total transaction of $191,362.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Julie Cooke sold 987 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $88.56, for a total value of $87,408.72. The disclosure for this sale can be found here. Insiders have sold 47,776 shares of company stock valued at $4,936,638 over the last 90 days. Insiders own 4.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC lifted its holdings in Neurocrine Biosciences by 6.1% in the second quarter. Janus Henderson Group PLC now owns 9,352,240 shares of the company’s stock worth $789,610,000 after acquiring an additional 540,279 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in Neurocrine Biosciences by 7.1% in the second quarter. Perceptive Advisors LLC now owns 4,023,862 shares of the company’s stock worth $339,734,000 after acquiring an additional 265,200 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Neurocrine Biosciences by 189.4% in the second quarter. Point72 Asset Management L.P. now owns 1,124,684 shares of the company’s stock worth $94,957,000 after acquiring an additional 735,992 shares during the last quarter. Pictet Asset Management Ltd. lifted its holdings in Neurocrine Biosciences by 9.6% in the third quarter. Pictet Asset Management Ltd. now owns 1,041,000 shares of the company’s stock worth $93,805,000 after acquiring an additional 91,310 shares during the last quarter. Finally, Nuveen Asset Management LLC bought a new position in Neurocrine Biosciences in the second quarter worth about $64,739,000. 97.15% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Read More: What are the economic characteristics of a bear market?

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Strs Ohio Has $29.96 Million Stake in Raytheon
Strs Ohio Has $29.96 Million Stake in Raytheon
Constellation Brands, Inc.  Shares Acquired by Strs Ohio
Constellation Brands, Inc. Shares Acquired by Strs Ohio
Strs Ohio Boosts Holdings in O’Reilly Automotive Inc
Strs Ohio Boosts Holdings in O’Reilly Automotive Inc
Kansas City Southern  Stake Reduced by Strs Ohio
Kansas City Southern Stake Reduced by Strs Ohio
Pivotal Research Increases Snap  Price Target to $24.50
Pivotal Research Increases Snap Price Target to $24.50
Lancaster Colony  Earns Buy Rating from Analysts at CL King
Lancaster Colony Earns Buy Rating from Analysts at CL King


© 2006-2020 Ticker Report